From : National Cancer Institute <nci@updates.cancer.gov>
To : tgabunia@moh.gov.ge
Subject : Selpercatinib for Lung Cancer with RET Alterations - Cancer Currents Blog
Received On : 27.09.2019 14:33
Selpercatinib for Lung Cancer with RET Alterations - Cancer Currents Blog
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.

 

 

Selpercatinib Shows Promise against Lung Cancers with Alterations in RET Gene
09/27/2019
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.
This email was sent to tgabunia@moh.gov.ge using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo